News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Celgene International Sárl (CELG) Release: Phase I/II Data Evaluating Clinical Benefit of REVLIMID(R) in Combination with Standard R-CHOP Chemotherapy for Patients with Untreated Diffuse Large B-Cell Lymphoma



6/16/2011 10:46:56 AM

BOUDRY, Switzerland--(BUSINESS WIRE)--Celgene International Sàrl (NASDAQ: CELG) announced that clinical data from two studies evaluating the use of REVLIMID® (lenalidomide) with standard R-CHOP* chemotherapy (R2CHOP) in patients with untreated diffuse large B cell (DLBCL) or grade 3 follicular lymphoma were presented at the 11th International Conference on Malignant Lymphoma in Lugano, Switzerland.

Read at BioSpace.com

Related News

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES